Market Access, Pricing & Reimbursement

Both public and private healthcare expenditures are coming under increasing pressure as costs rise as a fraction of GNP and new treatments outstrip patients’ ability to pay. The right pricing and market access strategy is essential to ensure patients can benefit from new therapies, as well as deliver commercial success for any new product launch. Irrespective of reimbursement status, it is vital to identify the best path to address price sensitivity and fast, reliable access routes to as many patients as possible. EVERSANA specializes in actionable solutions based on our deep understanding of pricing and access complexities presented by APAC markets and western markets of interest to Asian clients. Our services include:

Price sensitivity analysis using analogs sourced from our in-house proprietary data repository which is continuously updated
Assessment of reference pricing mechanisms and their likely impact across markets
Analysis of the acceptability of different pricing structures (flat, linear, non-linear)
Description of potential reimbursement scenarios based on opinions from our payer advisor network as a foundation for probability-based market opportunity assessments
Market research focused price sensitivity statistical tools to derive uptake at the practice level
Test Patient Affordability Program specific concepts to gauge commercial success in non-reimbursed markets

We have successfully advised our clients across the APAC region and western markets with varied levels of public reimbursement coverage.

Our Case Studies

Pricing Strategy for Chronic Diseases Across Asian Markets

Our client was launching an innovative treatment for a chronic disease and wished to identify price sensitivity in a crowded market. We analyzed analogs from our proprietary repository to review launch price points of other innovative medications and the resulting adjustment (reaction) across these markets. Our analysis provided a base line recommendation customized to each market.

Pricing & Market Access Strategy for an Innovative Oncology Asset

A global pharmaceutical company wished to identify the best pricing and market access strategy to maximize its market opportunity in select non-reimbursed Asian markets. We conducted price sensitivity analysis at the practice level using statistical tools to understand the impact of pricing scenarios on the overall opportunity size.

Asset Prioritization for Immunology Portfolio in China

An MNC with a portfolio of in-line and pipeline immunology products with overlapping indications wished to prioritize launch and repositioning of its assets in China. We conducted detailed assessments with relevant stakeholders such as ex-payer advisors and national KOLs to derive different pricing and market access scenarios and assessed the impact of each scenario on overall portfolio value to come out with prioritized list of assets, sequence of launch and indication expansion.

Pricing & Market Access Landscaping of an Early Phase Drug

A Japanese biopharma company was developing a novel biologic therapy in nephrology and wished to understand possible pricing and market access scenarios in the U.S. and EU5 countries. We analyzed current treatment and market landscapes of the disease and identified analogs. Through TPP assessment with payer advisors, we identified key value messages, cost-benefit expectations and acceptable pricing. We integrated findings and created different scenarios of pricing-based access to patient volumes.

Pricing & Market Access Landscape for a Western MNC in JAPAC

A western MNC had multiple pipeline oncology assets and wished to do a heuristic assessment of pricing and market access across JAPAC. We conducted comprehensive secondary and primary research as the basis for comparative analysis on contributing and impeding factors related to acceptable pricing and feasible market access routes. Our analysis helped the client prioritize and tailor their regional go-to-market strategy.